Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GalaNic: Low-Dose Galantamine and Nicotine for Attention
NCT02420327Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Sep 2014
- Primary completion
- Mar 2017
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Randomised, double-blind trial of galantamine in Alzheimer's disease (AD) and schizophrenia (4 arms), sponsored by University of Maryland, Baltimore. Primary endpoints: Spatial Attentional Resource Allocation Task Predictive Trials Reaction Time, Rapid Visual Information Processing Task Hit Rate and 4 more. Started Sep 2014; status: completed.
02
Drugs
galantamine
03
Conditions
Alzheimer's disease (AD)schizophrenia
Beyond the preview
Go deeper on NCT02420327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02420327.